Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States

Craver, Christopher; Gayle, Julie; Balu, Sanjeev; Buchner, Deborah

doi:10.3111/13696998.2010.547237

Cited by 39 publications

(27 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17,18 Nausea and vomiting are also common adverse effects of chemotherapy estimated to cost between $890 to $7680 per visit. 19,20 There were a total of 17 different treatment agents (15 chemotherapeutic) utilized among the 88 patients of this study. Of these agents, only 6 are recommended for use in CRPC by the National Comprehensive Cancer Network (NCCN).…”

Section: Discussionmentioning

confidence: 99%

Treatment Given Near the End of Life in Castration-Resistant Prostate Cancer

Zaghloul

Murillo

2012

Am J Hosp Palliat Care

View full text Add to dashboard Cite

Chemotherapy treatment options are limited for patients with castration-resistant prostate cancer (CRPC). The purpose of this study is to report treatment use and adverse effects (AEs) within the last three months of life in patients with CRPC. Of the 88 patients identified, 32% received treatment within 3 months of death, and documented AEs occurred in 25% of patients. Of those, neutropenia (18.3%), nausea/vomiting (18.3%), and febrile neutropenia (13.6%) were the most frequent. Results of this study show high treatment utility towards the end-of-life in patients with CRPC, with one fourth of patients experiencing AEs. Attention to health-related quality of life becomes increasingly important as new treatments appear to have small impact on survival, and AEs of those treatments may significantly impact patient quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment Given Near the End of Life in Castration-Resistant Prostate Cancer

Zaghloul

Murillo

2012

Am J Hosp Palliat Care

View full text Add to dashboard Cite

show abstract

“…Similarly, only 18% of the cost models used data sources outside of RCTs for AEs [72,74,75,87,88]. This trend points to a simple fact: while it is relatively easy to identify weaknesses in the RCT as a data source for informing patient value-choices, the identification of viable alternatives or complements is quite challenging.…”

Section: Synthesis Of Results Of Literature Evaluationsmentioning

confidence: 99%

“…The few prospective or patient-database driven economic evaluation studies in this review appear to provide a clearer picture of the frequency and nature of AEs, although the less controlled setting can make an estimation of treatment-attributable costs more challenging [72,74,75,87,88]. None of the value frameworks utilize non-RCT data this time.…”

Section: Patient-reported Outcomes and Quality Of Life Metricsmentioning

confidence: 99%

Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

Pettit

Kirch

2018

Cardio-Oncology

View full text Add to dashboard Cite

The increasing efficacy of cancer therapeutics means that the timespan of cancer therapy administration is undergoing a transition to increasingly long-term settings. Unfortunately, chronic therapy-related adverse health events are an unintended, but not infrequent, outcome of these life-saving therapies. Historically, the cardio-oncology field has evolved as retrospective effort to understand the scope, mechanisms, and impact of treatment-related toxicities that were already impacting patients. This review explores whether current systemic approaches to detecting, reporting, tracking, and communicating AEs are better positioned to provide more proactive or concurrent information to mitigate the impact of AE's on patient health and quality of life. Because the existing tools and frameworks for capturing these effects are not specific to cardiology, this study looks broadly at the landscape of approaches and assumptions. This review finds evidence of increasing focus on the provision of actionable information to support long-term health and quality of life for survivors and those on chronic therapy. However, the current means to assess and support the impact of this burden on patients and the healthcare system are often of limited relevance for an increasingly long-lived survivor and patient population.

show abstract

“…Adverse events impact patient quality of life and can result in treatment interruptions or dose reductions, which in turn may decrease treatment efficacy (Kayl and Meyers 2006; Hwang et al 2013). Furthermore, chemotherapy-related AEs can result in substantial increases in costs (Guerin et al 2011; Hurvitz et al 2012; Chu et al 2009; Stokes et al 2009; Craver et al 2011). …”

Section: Introductionmentioning

confidence: 99%

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens

Hansen

Ramsey

Lalla³

et al. 2014

SpringerPlus

View full text Add to dashboard Cite

PurposeWe sought to compare the economic impact of treatment-related adverse events (AEs) in patients with metastatic breast cancer (mBC) using taxane- or capecitabine-based treatment regimens as either first- or second-line (FL or SL) therapy in the US.MethodsWe used healthcare claims data from the Truven Health Analytics MarketScan® Commercial Databases to conduct a retrospective cohort study comparing the economic impact of AEs amongst taxane- and capecitabine-treated mBC patients in the US. We selected women diagnosed with mBC between 2008–2010 who received a taxane or capecitabine as first- or second-line (FL or SL) chemotherapy. Costs related to hospitalization, outpatient services, emergency department visits, chemotherapy and other medications were tabulated and combined to determine total healthcare costs. The incremental monthly costs associated with the presence of AEs compared to no AEs were estimated using generalized linear models, controlling for age and Charlson Comorbidity Index.ResultsWe identified 15,443 mBC patients meeting inclusion criteria. Adjusted total monthly costs were significantly higher in those who experienced AEs than in those without AEs in both lines of treatment (FL incremental cost: taxanes $1,142, capecitabine $1,817; SL incremental cost: taxanes $1,448, capecitabine $4,437). Total costs increased with the number of AEs and were primarily driven by increased hospitalization amongst those with AEs.ConclusionsAdverse events in taxane- or capecitabine-treated mBC patients are associated with significant increases in costs. Selecting treatment options associated with fewer AEs may reduce costs and improve outcomes in these patients.

show abstract

Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States

Abstract: In the current study analysis, a 20% CINV event rate per CT cycle per patient was predicted with an associated all-cause average daily total cost of approximately $1850. Further studies on early and appropriate antiemetic prophylaxis on CINV rates and economic outcomes are warranted.

Cited by 39 publications

References 20 publications

Treatment Given Near the End of Life in Castration-Resistant Prostate Cancer

Treatment Given Near the End of Life in Castration-Resistant Prostate Cancer

Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens

Contact Info

Product

Resources

About